Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer  + (Age in years, mean (SD): 61 (7.8))
• Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer  + (Age in years, mean (min-max) per arm: Selenium arm: 52.14 (22-81), placebo arm: 54.74 (18-81))
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (Age in years, mean (range): 63.49 (48-75))
• Ota et al. (2014): The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study  + (Age in years, mean: 64)
• Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial  + (Age in years, median (range): 58 (26-82))
• Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group  + (Age in years, median (range): 65 (31-85))
• Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2)  + (Age in years, median (range): 72 (66-74))

• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (Age in years: mean (SD) = 54.1 (10.41); range: 25-78)

• Panahi et al. (2012): Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial  + (Age range = 35-74 years, mean(SD) = 51.83(9.18) years)
• Raei et al. (2013): Effect of herbal therapy to intensity chemotherapy-induced nausea and vomiting in cancer patients  + (Age: 50.3 ± 13.1)
• Da Costa et al. (2009): Effectiveness of Guarana (Paullinia cupana) for Postradiation Fatigue and Depression Results of a Pilot Double-Blind Randomized Study  + (Average age of arm intervention-placebo = 59 years Average age of arm placebo-intervention = 57 years)
• Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer  + (Intervention arm: 42-74 (median: 56) Control arm: 41-73 (median: 58))
• Iovino et al. (2018): High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation  + (Intervention arm: 63 (49-72) Control arm: 58 (47-65))
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Intervention arm: MW (SD): 50 (11) Placebo arm: MW (SD): 51 (11))
• Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial  + (Intervention arm: MW (SD): 51.5 (3.3), Range: 18-70 Placebo arm: MW (SD): 47.2 (3.5), Range: 18-79)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Intervention arm: mean (SD): 47.53 (13.49), range: 21-65 placebo arm: mean (SD): 46.93 (14.39), range: 18-68)
• Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial  + (Intervention arm: mean (SD): 48.2 (15.3) Control arm: mean (SD): 4.3 (15.2))
• Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial  + (Intervention arm: mean (SD): 49.5 (17.47), Range: 18–78 placebo arm: mean (SD): 52.82 (14.03), Range: 22 –71)
• Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis  + (Intervention arm: mean (SD): 49.53 (13.75) Placebo arm: mean (SD): 50.88 (10.01))
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Intervention arm: mean (SD): 50 (11) Placebo arm: mean (SD): 51 (11))
• Rastelli et al. (2011): Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial  + (Intervention arm: mean (SD): 60 (8.8) Placebo arm: mean (SD): 63 (7.8))
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Intervention arm: mean (SD): 62 (13) Placebo arm: mean (SD): 60 (12))
• Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer  + (Intervention arm: mean (SD): 62.5 (7.5) Placebo arm: mean (SD): 63.8 (13.3))
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Intervention arm: mean: 62 (43–78) Placebo arm: mean: 60 (29–77))
• Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer  + (Intervention arm: mean: 67.4 (53-78) Control arm: mean: 62.7 (35-86))
• Scher et al. (2011): Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer  + (Intervention arm: mean: 70.4 Control arm: mean: 70.9)
• Jacot et al. (2016): Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study  + (Intervention arm: median (range): 51 (27-74) Control arm: median (range): 49 (25-71))
• Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators  + (Intervention arm: median (range): 68 (45-87) Placebo arm: median (range): 70 (47-92))
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (Intervention arm: median (range): 72.0 (50.0-85.0) Placebo arm: median (range): 70.0 (52.0-82.0))
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (Intervention arm: median and interquartile ranges of age at diagnosis: 60.5 (55-71) Placebo arm: median and interquartile ranges of age at diagnosis: 62 (54-69))
• Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial  + (Intervention arm: median=54 (interquartile range: 47-65); placebo arm: median: 56 (interquartile range: 50-64))
• Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial  + (Intervention arm: median=54 (interquartile range: 47-65); placebo arm: median: 56 (interquartile range: 49-65))
• Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer  + (MW (SD): 63 (15))